liu.seSearch for publications in DiVA
Change search
ReferencesLink to record
Permanent link

Direct link
Prevalence of human T-lymphotropic virus type 1 and 2 infection in Sweden
Örebro University Hospital, Sweden .
Linköping University, Department of Clinical and Experimental Medicine, Transfusion Medicine. Linköping University, Faculty of Health Sciences. Östergötlands Läns Landsting, Centre for Diagnostics, Department of Clinical Immunology and Transfusion Medicine.
Maria Beroendecentrum, Centre for Dependency Disorders, Stockholm, Sweden.
Karolinska University Hospital, Sweden .
Show others and affiliations
2012 (English)In: Scandinavian Journal of Infectious Diseases, ISSN 0036-5548, Vol. 44, no 11, 852-859 p.Article in journal (Refereed) Published
Abstract [en]

Background: Prevalence data on human T-lymphotropic virus types 1 and 2 (HTLV-1/2) in Sweden have not been updated since 1995. The seroprevalence among blood donors at that time was 0.2/10,000. A few years earlier, a high prevalence of HTLV-2 was found in intravenous drug users (IDUs) in Stockholm (3.4%). The objective of this study was to update information on the seroprevalence of HTLV in several study groups. Methods: Serum samples from pregnant women, hepatitis C virus (HCV)-positive individuals, and IDUs in Stockholm were investigated for HTLV-1/2 antibodies. Data from the mandatory HTLV-1/2 screening (2003-2006) of in vitro fertilization (IVF) clients were compiled, as well as data from new blood donors. Results: Eight out of 35,000 IVF patients were positive for anti-HTLV-1/2 (seroprevalence 2.3 per 10,000). Of the anti-HCV-positive individuals (n = 355), 1 sample was HTLV-1-positive (28.2 per 10,000). From 1995 to 2007, 18 HTLV-positive new blood donors were identified out of approximately 550,000 individuals tested (0.3 per 10,000). Thirty-five of 1079 tested IDUs were screening reactive. Conclusions: Since the start of screening in 1994, there has been no increased seroprevalence of HTLV-1/2 among blood donors in Sweden. Seroprevalence among Swedish IVF patients is 10 times higher than among blood donors. This finding is comparable to a 2003 European seroprevalence study of pregnant women in 7 countries. However, the possibility that the IVF group includes individuals with a higher risk of acquiring sexually transmitted infections, including HTLV, than the general population cannot be ruled out.

Place, publisher, year, edition, pages
Informa Healthcare , 2012. Vol. 44, no 11, 852-859 p.
Keyword [en]
HTLV-1/2, prevalence, IDU, blood donors, IVF
National Category
Medical and Health Sciences
URN: urn:nbn:se:liu:diva-85625DOI: 10.3109/00365548.2012.689847ISI: 000310008900008OAI: diva2:572061
Available from: 2012-11-26 Created: 2012-11-26 Last updated: 2012-12-03

Open Access in DiVA

No full text

Other links

Publisher's full text

Search in DiVA

By author/editor
Ekermo, Bengt
By organisation
Transfusion MedicineFaculty of Health SciencesDepartment of Clinical Immunology and Transfusion Medicine
In the same journal
Scandinavian Journal of Infectious Diseases
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 39 hits
ReferencesLink to record
Permanent link

Direct link